Natco Pharma Limited has disclosed the acquisition of Eywa Pharma Pte Ltd, a Singapore-based pharmaceutical company with a consolidated gross revenue of US$ 19.16 million for 2023. The acquisition is not a related party transaction and the nature of consideration is a cash consideration of US$ 3 million. Natco Pharma Limited now holds a 7.07% shareholding in Eywa Pharma.